BC3448
Not Specified (Oncology)
Phase 1First patient dosed (2022)
Key Facts
Indication
Not Specified (Oncology)
Phase
Phase 1
Status
First patient dosed (2022)
Company
About BioCity Biopharma
A clinical-stage biopharma developing novel BIC/FIC therapeutics for oncology and nephrology, with a multi-modality pipeline and global clinical operations.
View full company profileTherapeutic Areas
Other Not Specified (Oncology) Drugs
| Drug | Company | Phase |
|---|---|---|
| IMGS-203 | ImmunoGenesis | Pre-clinical |
| XNW28012 | Evopoint Biosciences | Phase 3 |
| Anti-TM4SF4 Antibody | Algok Bio | Preclinical |
| Oncology 1 | Actipulse Neuroscience | Pre-clinical |
| SynKIR™-310 | Verismo Therapeutics | Phase 1 |
| AUR112 | Aurigene Oncology | Phase 1 |
| B7H3 Antibody-Drug Conjugate | Ellipses Pharma | Clinical |
| BC2027 | BioCity Biopharma | Phase 1 |